In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants  by Negri, Maria-Cristina & Baquero, Fernando
In vitro selective concentrations of cefepime and 
ceftazidime for AmpC P-lactamase hyperproducer 
Enterobacter cloacae variants 
Clin Microbiol Infeect 1999; 5: S25-S28 
Maria- Cristina Negri and Fernando Baquero 
Department of Microbiology, R a m 6 n  y Cajal Hospital, National Institute of Health (INSALUD), 
28034 Madrid, Spain 
This study aimed to compare the selective concentrations of cefepime and ceftazidime on Enterobacter cloacae. A mixed 
culture of a wild-type ceftazidime/cefepime-susceptible (4x lo7 CFU/mL) strain and an ampC derepressed Enterobacter 
cloacae (lo5 CFU/mL) strain (relative proportions 99.75% and 0.25%) was challenged for 4 h with different antibiotic 
concentrations of ceftazidime and cefepime (0.03-4096 mg/L), and then transferred to  drug-free medium. The proportion 
of wild-type versus derepressed population was evaluated after 24 h. 
Ceftazidime and cefepirne selected the derepressed variant at concentrations ranging from 1 to 4096 and from 0.12 to 
16 mg/L respectively. 
These results suggest that serum concentrations attainable with a 2 g/8 h cefepime dosage may be able to suppress the 
emergence of derepressed ampC mutants. 
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One of the major problems in current p-lactam therapy 
is the emergence of high-level resistance Enterobacter 
variants during therapy with third-generation cephalo- 
sporins [1,2]. This type of mutant, frequently carrying 
an am@ mutation [ 3 ] ,  is generally present in the 
original population at  a relatively high level, to 
lo-’. Antibiotics such as cefotaxime or ceftazidime are 
efficiently hydrolyzed by the AmpC enzyme, and this 
is why constitutive hyperproducer variants were able 
to resist high concentrations of these drugs, and there- 
fore are selected (‘emerge’) during therapy. The major 
theoretical advantage of some new cephalosporin 
derivatives, such as cefepime, is the reduced AmpC 
enzyme afinity for these compounds. Because of that, 
the variant hyperproducer population is not expected 
to be efficiently selected [4]. 
Theoretically, the selection of antibiotic-resistant 
variants should occur at particular selective antibiotic 
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concentrations (SACS) [5,6], defined as the concentra- 
tions inhibiting the susceptible population but not the 
resistant variants. From the clinical point of view, it is 
appropriate to know the antibiotic concentrations at 
which the resistant variants are expected to be selected, 
in order to avoid as much as possible the maintenance 
of these concentrations in the infected site, and thus to 
prevent the emergence of resistance during treatment. 
In this paper an in vitro modeling procedure, which 
involves the building up of bacterial populations after a 
limited challenge with different antibiotic concentra- 
tions, is proposed. 
MATERIALS AND METHODS 
Strains 
The strain Enterobacter cloacae RYC12991, a clinical 
isolate, was used as a ‘susceptible’ strain. The strain 
had the following MICs, as determined by conven- 
tional methods: ceftazidime 0.5 mg/L, and cefepime 
0.5 mg/L 171. A nalidixic acid-resistant variant strain 
(MIC >64 mg/L) was obtained by one-step selection 
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on plates containing 50 mg/L of nalidixic acid; the 
strain was named RYC12991-Wrq. A ceftazidime- 
resistant variant strain (ceftazidime MIC, 1024 mg/L; 
cefepime MIC, 16 mg/L) was obtained by seeding a 
dense inoculum of RYC12991 on plates containing 
200 mg/L of ceftazidime. This strain hyperproduced 
(>lo0 000 U/mg of protein) a PI 7.8 AmpC-type 
P-lactamase, and was named RYC12991-D. 
Fitness analysis 
In order to calculate the eventual disadvantage that the 
mutant hyperproducer P-lactamase strain may have 
when competing with the wild-type strain (‘cost’ of 
antibiotic resistance), both populations were mixed 
at identical density (7x104/mL), seeded on 5 mL 
Mueller-Hinton (MH) broth, and incubated over- 
night. Immediately after the mixture was prepared, and 
after overnight incubation, non-antibiotic-containing 
MH plates were seeded, and 100 colonies were studied 
on nalidixic acid agar plates and control plates, to 
calculate the proportion of each strain after incubation. 
A new 5-mL tube was inoculated with the overnight 
culture, and the same procedure was repeated for 6 
days. The final proportions of RYC12991-Wrq and 
RYC 12991 -D were established after this time by seeding 
on non-antibiotic- and nalidixic acid-containing agar 
plates. Experiments were carried out in triplicate. 
Selection of the resistant population 
A mixture was prepared with exponential MH broth 
cultures of RYC12991-Wrq and RYC12991-D in the 
following proportions: 4x10’ and 1 x105 CFU/mL 
(99.75% and 0.25% respectively). MH 5-mL tubes 
containing ceftazidime or cefepime (range 0.03- 
4096 mg/L) were setded with the mixture, and 
incubated for 4 h at 37°C; aliquots from each tube were 
then transferred to drug-free MH broth tubes. After 
overnight incubation, dilutions of each tube were 
seeded in MH agar plates without antibiotic. After 
18 h, 100 isolated colonies selected at random from 
each plate were spotted onto MH control plates and on 
MH plates containing 50 mg/L of nalidixic acid. 
Nalidixic acid-resistant spots obtained from antibiotic 
concentrations over 1 mg/L of ceftazidime or 
0.12 mg/L of cefepime were controlled for ceftazidime 
susceptibility after a week of daily passages in drug-free 
medium, in order to detect a reversible phenotype of 
an induced RYC12991-Wrq strain. All experiments 
were done at least in duplicate. 
RESULTS 
Fitness analysis 
In the absence of antibiotic selection, the resistant strain 
RYC12991-D had a strong disadvantage in replication 
rate if compared with the wild strain. After overnight 
culture, the proportion of this resistant strain dropped 
from 58% to 19%. Not a single colony of this resistant 
strain was recovered among 100 colonies analyzed 
after 6 days of co-cultivation with the susceptible 
population. 
Selection of derepressed population in mixed cultures 
Under our experimental conditions, the susceptible E. 
cloacae RYC12991-Wrq strain began to lose represent- 
ation in 24-h populations resulting from mixed inocula 
challenged for 4 h with a ceftazidime concentration of 
1 mg/L. A very sharp decrease in the original propor- 
tion occurred after a challenge of 2 mg/L, with a heavy 
selection of the resistant mutant, which reached more 
than 90% of the total population. In concentrations 
ranging from 4 to 256 mg/L, a small percentage of the 
susceptible RYC12991-Wrq strain remained in the 
total population. All nalidixic acid-resistant colonies 
isolated from the 4-256 mg/L cultures regained total 
susceptibility to ceftazidime or cefepime after passage 
in drug-free medium. Above a concentration of 
256 mg/L of ceftazidime, all colonies corresponded to 
the derepressed variant (Figure 1). Therefore, the 
theoretical selective concentrations interval (the 
‘selective window’) for ceftazidime was in our case 1 to 
>4096 mg/L. It is expected that any concentration in 
this range will be strongly selective for the hyper- 
producer variant strain. 
In the case of cefepime, the susceptible E. cloacae 
RYC12991-Wrq population sharply disappeared in a 
sample of 100 colonies of the 24-h population after the 
4-h treatment of the mixture with only 0.12 mg/L, and 
the same effect was obtained with higher concentra- 
tions. As expected, the RYC12991-D strain appeared 
as the predominant population (more than 98%) in 24- 
h cultures obtained after challenge with 0.12 mg/L for 
4 h. After a challenge of 0.12-16 mg/L of cefepime, 
the RYC12991-D strain constituted more than 97% 
of the recovered colonies (Figure 1). In populations 
challenged with 0.12-4 mg/L, a small proportion of 
induced RYC12291-Wrq was detected. Interestingly, 
no growth was obtained with a challenge of over 
16mg/L of cefepime. Thus, in our experimental 
conditions, the cefepime selective concentrations 
interval for the hyperproducer variant was 
0.12-16 mg/L. 
Serum pharmacokinetics and selective windows for 
ceftazidime and cefepime 
Ceftazidime and cefepime have very similar pharma- 
cokinetic parameters, with C,, values of about 180 
and 130 mg/L after a 2000-mg intravenous dose (the 
concentrations are roughly proportional to the dose), 
and tl,* values of 1.8 and 2.1 h respectively. For the case 
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Figure 1 Proportion of wild-type E. cloacae RYC12991 strain (white bars), and constitutively derepressed variants 
hyperproducing AmpC (black bars), after a 4-h challenge with different concentrations of ceftazidime (upper part) or 
cefepime (lower part), followed by a 24-h period of growth in antibiotic-free medium. 
of the E .  cloacae model studied in this work, and after 
a single 2-g intravenous dose, ceftazidime is expected 
to achieve selective concentrations almost immediately, 
and these concentrations will be maintained for 13.8 h 
(Figure 2). O n  the contrary, after 2 g of intravenous 
cefepime, there is a period of 7.4 h above the selective 
concentrations; then, the curve enters into the selective 
area for 13.8 h (Figure 2). With a 1-g dose, ceftazidime 
reduces the immediate selective time from 13.8 to 
11.8 h. In the case of cefepime, the reduction of the 
dose from 2 to 1 g is expected to decrease from 7.4 to 
5.4 h the selective-free period after injection. Within 1 
day, the length of the selective period does not 
significantly change for 1- or 2-g cefepime doses, being 
nearly 13.7 h in all cases. 
In many cases, what are incorrectly called ‘rates of 
mutation’ are in fact ‘rates of selection’ of the different 
antibiotics, depending on their intrinsic activity on the 
mutant subpopulation, or, in other words, on the 
differential activity on wild (susceptible) and mutant 
(resistant) populations. In most cases, this differential 
activity is reflected by a new ‘proportion’ of susceptible 
and resistant strains in populations resulting from 
growth of the surviving cells after antibiotic challenge 
[S]. This differential activity, considered together with 
the expected antibiotic concentrations in the human 
body at different times, expresses the ‘selective window’ 
of concentrations for each antibiotic (Figure 2). 
The model studied here predicts that in the case 
of ceftazidime 1 or 2 g every 8 or 12 h, a continuous 
selective window for resistant Enterobacter variants 
should occur. O n  the contrary, in the case of cefepime, 
the model suggests that a therapeutic schedule based on 
the intravenous administration of 2 g every 8 h should 
be only weakly selective for derepressed Enterobacter 
mutants. This schedule should produce three very 
short selective periods of 0.6 h/day, the blood levels 
being maintained over the concentration selecting 
RYC12991-D during 22.2 h/day. Nevertheless, with a 
12-h schedule, two selective windows of 4.6 h may 
occur every 24 h, during which selection of resistant 
Enterobacter is expected to occur. In the case of a 
schedule based on 1 g cefepime every 8 h, three 
selective periods of 2.6 h/day can be predicted. With 
1 g every 12 h, two 6.6-h selective periods per day are 
expected. In summary, according to this model, the 
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Figure 2 Expected serum levels of cefiazidime (A) or  cefepime (M) after a single intravenous administration of 1 g (A) or 
2 g (B). The frames show the time periods where the concentrations may be selective for the constitutively AmpC p- 
lactamase hyperproducer E. cloacae RYC12991 strain. 
potential advantage of cefepime over ceftazidime is 
based on its shorter risk period for selection of 
derepressed Enterobacter mutants. This advantage is 
evident with a 2-g dosage and particularly important in 
a three times a day schedule. In the case of the presence 
of derepressed mutants that were selected by cefepime 
8mg/L (instead of 16 mg/L as in our model), 
intravenous administration of 2 g/8 h is expected to 
completely suppress the emergence of the resistant 
population. Studies focused on understanding the 
mechanisms of selection of bacterial resistant popula- 
tions according to the pharmacokinetics of the 
antibiotics with different dosage patterns are urgently 
required. 
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